-
GEN – Genetic Engineering & Biotechnology News2 weeks ago
Epigenetic Memory from Inflammation May Prime the Gut for Colon Cancer
It is well known that chronic inflammation can increase a person’s cancer risk, but the underlying mechanisms remain unknown. Now, a new study reveals, in a...
-
BioPharma Dive – AI / Data2 weeks agoMaze tumbles despite positive data for kidney disease drug
Investors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease.
-
Endpoints News2 weeks ago
FDA gives Denali accelerated approval for rare disease drug
The FDA granted accelerated approval to Denali Therapeutics’ rare disease drug Avlayah, bucking a recent trend of rejections in the space that has put the agency...
-
Uncategorized2 weeks ago
Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data
Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung up” with the broad population data in Maze...
-
Biotech Industry Intelligence2 weeks ago
Maze Loses Nearly a Third of Market Share on Mixed Midstage Kidney Drug Data
Maze Loses Nearly a Third of Market Share on Mixed Midstage Kidney Drug Data
-
STAT News – Biotech2 weeks agoCalifornia considers seal of approval for foods that are not ultra-processed
A new California bill continues the state’s efforts to crack down on ultra-processed foods, proposing a front-of-package seal that manufacturers could place on their products to...
-
Endpoints News2 weeks ago
More changes ahead for Takeda with new CEO set to take reins
Takeda’s multi-year restructuring will continue under incoming CEO Julie Kim. The company announced Wednesday that the board has approved “next steps” in its transformation that will...
-
STAT News – Biotech2 weeks agoSTAT+: Bhattacharya addresses CDC director role, works to bolster staff morale in first all-hands meeting
Centers for Disease Control and Prevention staff gathered Wednesday for what many hoped would be an announcement of the Trump administration’s choice for a new leader...
-
Endpoints News2 weeks ago
How Seaport is hedging against failure in Phase 2b depression study
Seaport Therapeutics is building a fail-safe into its Phase 2b depression trial. The biotech is testing its drug, called SPT-300, in patients with major depressive disorder....
-
STAT News – Biotech2 weeks agoHeart failure is common. A quick MRI could improve diagnosis and guide treatment
Hearts need oxygen. Heart attacks are the most dramatic example of this hunger, when blocked coronary arteries starve muscles of the oxygen they need to keep...
